The estimated Net Worth of Point Llc Loeb Daniel S Third is at least $1.83 Миллиард dollars as of 16 May 2019. Point Third owns over 5,000,000 units of Baxter International stock worth over $903,529,029 and over the last 9 years Point sold BAX stock worth over $930,810,000.
Point has made over 2 trades of the Baxter International stock since 2018, according to the Form 4 filled with the SEC. Most recently Point sold 5,000,000 units of BAX stock worth $381,850,000 on 16 May 2019.
The largest trade Point's ever made was selling 8,000,000 units of Baxter International stock on 3 December 2018 worth over $548,960,000. On average, Point trades about 4,333,333 units every 55 days since 2015. As of 16 May 2019 Point still owns at least 23,008,124 units of Baxter International stock.
You can see the complete history of Point Third stock trades at the bottom of the page.
Point's mailing address filed with the SEC is 390 Park Ave, New York, NY 10022, USA.
Over the last 21 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney и Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: